ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 040,12
0,42%
Dow Jones
38 886,17
0,20%
DAX
18 652,67
0,44%
Brent Oil
79,88
1,68%
Bitcoin
70 783,55
-0,41%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Affimed NV (AFMD)

  7. Affimed NV (AFMD) Actualités

AFMD

Affimed NV (AFMD)

Affimed NV
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AFMD
DateHeureSourceTitreSymboleSociété
06/06/202423h13Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:AFMDAffimed NV
05/06/202412h30GlobeNewswire Inc.Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024NASDAQ:AFMDAffimed NV
03/06/202412h04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
01/06/202419h02GlobeNewswire Inc.Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant CohortNASDAQ:AFMDAffimed NV
29/05/202412h30GlobeNewswire Inc.Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung CancerNASDAQ:AFMDAffimed NV
28/05/202412h30GlobeNewswire Inc.Affimed Announces Annual General Meeting of ShareholdersNASDAQ:AFMDAffimed NV
23/05/202423h05GlobeNewswire Inc.Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024NASDAQ:AFMDAffimed NV
14/05/202416h05GlobeNewswire Inc.Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 CongressNASDAQ:AFMDAffimed NV
24/04/202410h05GlobeNewswire Inc.Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical OncologyNASDAQ:AFMDAffimed NV
28/03/202411h30GlobeNewswire Inc.Affimed Reports 2023 Financial Results and Operational ProgressNASDAQ:AFMDAffimed NV
21/03/202411h30GlobeNewswire Inc.Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024NASDAQ:AFMDAffimed NV
06/03/202412h30GlobeNewswire Inc.Affimed Announces 1-for-10 Reverse Stock SplitNASDAQ:AFMDAffimed NV
08/01/202422h05GlobeNewswire Inc.Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung CancerNASDAQ:AFMDAffimed NV
08/01/202414h00GlobeNewswire Inc.Affimed Announces Leadership Change and Organizational RestructuringNASDAQ:AFMDAffimed NV
03/01/202412h30GlobeNewswire Inc.Affimed Announces Sale of Wholly-Owned Subsidiary AbCheckNASDAQ:AFMDAffimed NV
11/12/202312h02GlobeNewswire Inc.Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer PatientsNASDAQ:AFMDAffimed NV
11/12/202312h00GlobeNewswire Inc.Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)NASDAQ:AFMDAffimed NV
04/12/202312h30GlobeNewswire Inc.Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24NASDAQ:AFMDAffimed NV
14/11/202312h30GlobeNewswire Inc.Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational ProgressNASDAQ:AFMDAffimed NV
09/11/202312h30GlobeNewswire Inc.Affimed Announces Acimtamig as International Nonproprietary Name for AFM13NASDAQ:AFMDAffimed NV
07/11/202312h30GlobeNewswire Inc.Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023NASDAQ:AFMDAffimed NV
03/11/202317h05GlobeNewswire Inc.Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of CancerNASDAQ:AFMDAffimed NV
02/11/202314h05GlobeNewswire Inc.Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual MeetingNASDAQ:AFMDAffimed NV
01/11/202311h30GlobeNewswire Inc.Affimed to Participate in Upcoming Investor ConferencesNASDAQ:AFMDAffimed NV
04/10/202312h30GlobeNewswire Inc.Affimed Announces Listing Transfer to Nasdaq Capital MarketsNASDAQ:AFMDAffimed NV
27/09/202315h05GlobeNewswire Inc.Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of CancerNASDAQ:AFMDAffimed NV
21/09/202312h30GlobeNewswire Inc.Affimed to Present at the Cantor Global Healthcare Conference 2023NASDAQ:AFMDAffimed NV
12/09/202312h30GlobeNewswire Inc.Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin LymphomaNASDAQ:AFMDAffimed NV
07/09/202312h30GlobeNewswire Inc.Affimed to Present at the H.C. Wainwright Annual Global Investment ConferenceNASDAQ:AFMDAffimed NV
22/08/202311h00GlobeNewswire Inc.Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal DevelopabilityNASDAQ:AFMDAffimed NV
 Showing the most relevant articles for your search:NASDAQ:AFMD

Dernières Valeurs Consultées

NASDAQ
FHTCBX
Fhtc Balanced
AMEX
PNS
Pinnacle Data Sys In
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés